CLIRNET

Call Directions Website Contact the practice

CLIRNET Founded in 2015, we empower 650,000+ HCPs globally with Real-World Evidence (RWE)-driven insights.

Our diverse 250+ team (65% women) drives MedWikiยฎ, a platform with 1M+ clinical content pieces, fostering inclusivity and innovation. CLIRNet is creating a network of Indian Physicians who often lack basic infrastructure by meeting their needs on the ground, thereby making it the go-to platform for healthcare companies to market their products and services in an ethical, impactful, and cost-effective manner. CLIRNET enables physicians to expand their reach across the community, add variety in process of information exchange, and most importantly bridge the knowledge divide to enable seamless and quality delivery of patient care across India.

๐ƒ๐จ๐œ๐ญ๐จ๐ซ๐ฌ ๐๐ข๐๐งโ€™๐ญ ๐ง๐ž๐ž๐ ๐š๐ง๐จ๐ญ๐ก๐ž๐ซ ๐ฉ๐ฅ๐š๐ญ๐Ÿ๐จ๐ซ๐ฆ. They needed a reason to believe in one. ๐ŸŽฏโฃAnd that became the real challenge.โฃTurn...
13/08/2026

๐ƒ๐จ๐œ๐ญ๐จ๐ซ๐ฌ ๐๐ข๐๐งโ€™๐ญ ๐ง๐ž๐ž๐ ๐š๐ง๐จ๐ญ๐ก๐ž๐ซ ๐ฉ๐ฅ๐š๐ญ๐Ÿ๐จ๐ซ๐ฆ. They needed a reason to believe in one. ๐ŸŽฏโฃ
And that became the real challenge.โฃ
Turning scepticism into adoption.โฃ
Turning technology into trust.โฃ
Turning a traditional healthcare ecosystem into ๐š ๐œ๐จ๐ง๐ง๐ž๐œ๐ญ๐ž๐ ๐๐ข๐ ๐ข๐ญ๐š๐ฅ ๐ง๐ž๐ญ๐ฐ๐จ๐ซ๐ค.โฃ
โฃ
Today, that journey reaches ๐Ÿ”๐Ÿ“๐ŸŽ,๐ŸŽ๐ŸŽ๐ŸŽ+ ๐ก๐ž๐š๐ฅ๐ญ๐ก๐œ๐š๐ซ๐ž ๐ฉ๐ซ๐จ๐Ÿ๐ž๐ฌ๐ฌ๐ข๐จ๐ง๐š๐ฅ๐ฌ ๐š๐œ๐ซ๐จ๐ฌ๐ฌ ๐Ÿ‘๐ŸŽ+ ๐œ๐จ๐ฎ๐ง๐ญ๐ซ๐ข๐ž๐ฌ. ๐ŸŒโฃ
Doctors are trained to rely on evidence, experience and systems they trust. Asking them to adopt a new digital ecosystem is not simply asking them to use another platformโ€”it is asking them to ๐œ๐ก๐š๐ง๐ ๐ž ๐š ๐ก๐š๐›๐ข๐ญ ๐›๐ฎ๐ข๐ฅ๐ญ ๐จ๐ฏ๐ž๐ซ ๐ฒ๐ž๐š๐ซ๐ฌ.โฃ

๐ˆ๐ญโ€™๐ฌ ๐š๐›๐จ๐ฎ๐ญ ๐œ๐ก๐š๐ง๐ ๐ข๐ง๐  ๐ก๐จ๐ฐ ๐๐จ๐œ๐ญ๐จ๐ซ๐ฌ ๐œ๐จ๐ง๐ง๐ž๐œ๐ญ, ๐ฅ๐ž๐š๐ซ๐ง, ๐œ๐จ๐ฅ๐ฅ๐š๐›๐จ๐ซ๐š๐ญ๐ž ๐š๐ง๐ ๐š๐œ๐œ๐ž๐ฌ๐ฌ ๐ข๐ง๐ญ๐ž๐ฅ๐ฅ๐ข๐ ๐ž๐ง๐œ๐žโ€”๐ฐ๐ข๐ญ๐ก๐จ๐ฎ๐ญ ๐ฅ๐จ๐ฌ๐ข๐ง๐  ๐ญ๐ก๐ž ๐ญ๐ซ๐ฎ๐ฌ๐ญ ๐ญ๐ก๐š๐ญ ๐ฆ๐ž๐๐ข๐œ๐ข๐ง๐ž ๐ข๐ฌ ๐›๐ฎ๐ข๐ฅ๐ญ ๐จ๐ง.โฃ
โฃ
In this conversation, ๐Œ๐ซ. ๐’๐š๐ฎ๐ซ๐š๐ฏ ๐Š๐š๐ฌ๐ž๐ซ๐š, ๐‚๐จ-๐Ÿ๐จ๐ฎ๐ง๐๐ž๐ซ, reflects on the journey from โ€œWhy do we need this?โ€ to building one of the worldโ€™s largest physician intelligence networks.โฃ
โฃ
๐“๐ก๐ž ๐›๐ข๐ ๐ ๐ž๐ฌ๐ญ ๐ญ๐ซ๐š๐ง๐ฌ๐Ÿ๐จ๐ซ๐ฆ๐š๐ญ๐ข๐จ๐ง ๐ฐ๐š๐ฌ๐งโ€™๐ญ ๐ญ๐ž๐œ๐ก๐ง๐จ๐ฅ๐จ๐ ๐ข๐œ๐š๐ฅ. ๐ˆ๐ญ ๐ฐ๐š๐ฌ ๐›๐ž๐ก๐š๐ฏ๐ข๐จ๐ฎ๐ซ๐š๐ฅ.โฃ
โฃ
๐Ÿ”— Read the full piece:โฃโฃ
https://helloentrepreneurs.com/e-magazine/june-2026/โฃ
โฃ

A major advance in post-transplant immunotherapy. The FDA has approved the ๐Ÿ๐ข๐ซ๐ฌ๐ญ ๐ซ๐ž๐ ๐ฎ๐ฅ๐š๐ญ๐จ๐ซ๐ฒ ๐“-๐œ๐ž๐ฅ๐ฅ (๐“๐ซ๐ž๐ )-๐›๐š๐ฌ๐ž๐ ๐ข๐ฆ๐ฆ๐ฎ๐ง๐จ๐ญ๐ก...
11/08/2026

A major advance in post-transplant immunotherapy. The FDA has approved the ๐Ÿ๐ข๐ซ๐ฌ๐ญ ๐ซ๐ž๐ ๐ฎ๐ฅ๐š๐ญ๐จ๐ซ๐ฒ ๐“-๐œ๐ž๐ฅ๐ฅ (๐“๐ซ๐ž๐ )-๐›๐š๐ฌ๐ž๐ ๐ข๐ฆ๐ฆ๐ฎ๐ง๐จ๐ญ๐ก๐ž๐ซ๐š๐ฉ๐ฒ ๐Ÿ๐จ๐ซ ๐š๐๐ฎ๐ฅ๐ญ๐ฌ ๐ฐ๐ข๐ญ๐ก ๐ก๐ข๐ ๐ก-๐ซ๐ข๐ฌ๐ค ๐›๐ฅ๐จ๐จ๐ ๐œ๐š๐ง๐œ๐ž๐ซ๐ฌ ๐ฎ๐ง๐๐ž๐ซ๐ ๐จ๐ข๐ง๐  ๐š๐ฅ๐ฅ๐จ๐ ๐ž๐ง๐ž๐ข๐œ ๐ก๐ž๐ฆ๐š๐ญ๐จ๐ฉ๐จ๐ข๐ž๐ญ๐ข๐œ ๐ฌ๐ญ๐ž๐ฆ ๐œ๐ž๐ฅ๐ฅ ๐ญ๐ซ๐š๐ง๐ฌ๐ฉ๐ฅ๐š๐ง๐ญ๐š๐ญ๐ข๐จ๐ง (๐‡๐’๐‚๐“). โฃ

โฃ
In the Phase 3 PRECISION-T trial, ๐Ÿ•๐Ÿ–% ๐จ๐Ÿ ๐ฉ๐š๐ญ๐ข๐ž๐ง๐ญ๐ฌ ๐ซ๐ž๐ฆ๐š๐ข๐ง๐ž๐ ๐š๐ฅ๐ข๐ฏ๐ž ๐š๐ง๐ ๐Ÿ๐ซ๐ž๐ž ๐จ๐Ÿ ๐ฆ๐จ๐๐ž๐ซ๐š๐ญ๐ž-๐ญ๐จ-๐ฌ๐ž๐ฏ๐ž๐ซ๐ž ๐œ๐ก๐ซ๐จ๐ง๐ข๐œ ๐ ๐ซ๐š๐Ÿ๐ญ-๐ฏ๐ž๐ซ๐ฌ๐ฎ๐ฌ-๐ก๐จ๐ฌ๐ญ ๐๐ข๐ฌ๐ž๐š๐ฌ๐ž (๐œ๐†๐•๐‡๐ƒ) ๐š๐ญ ๐Ÿ ๐ฒ๐ž๐š๐ซ versus ๐Ÿ‘๐Ÿ–.๐Ÿ’% with standard transplantation, while ๐ฆ๐จ๐๐ž๐ซ๐š๐ญ๐ž-๐ญ๐จ-๐ฌ๐ž๐ฏ๐ž๐ซ๐ž ๐œ๐†๐•๐‡๐ƒ ๐ฐ๐š๐ฌ ๐ซ๐ž๐๐ฎ๐œ๐ž๐ ๐Ÿ๐ซ๐จ๐ฆ ๐Ÿ’๐Ÿ’% ๐ญ๐จ ๐Ÿ๐Ÿ.๐Ÿ”%.โฃ


07/08/2026

"Your newborn doesn't ask for expensive toys. Only one thing โ€” your first embrace and your first milk." ๐Ÿคฑโฃ
โฃ
Dr. Omesh Khurana, Senior Paediatrician, leaves us with the simplest and most powerful reminder of this ๐–๐จ๐ซ๐ฅ๐ ๐๐ซ๐ž๐š๐ฌ๐ญ๐Ÿ๐ž๐ž๐๐ข๐ง๐  ๐–๐ž๐ž๐ค.โฃ
โฃ
No equipment. No cost. No substitute.โฃ
โฃ
Just you. ๐Ÿ’™โฃ
โฃ

Addressing ๐š๐œ๐ก๐จ๐ง๐๐ซ๐จ๐ฉ๐ฅ๐š๐ฌ๐ข๐š at its source ๐ˆ๐ง๐Ÿ๐ข๐ ๐ซ๐š๐ญ๐ข๐ง๐ข๐›, ๐š๐ง ๐จ๐ซ๐š๐ฅ ๐…๐†๐…๐‘๐Ÿโ€“๐Ÿ‘ ๐ญ๐ฒ๐ซ๐จ๐ฌ๐ข๐ง๐ž ๐ค๐ข๐ง๐š๐ฌ๐ž ๐ข๐ง๐ก๐ข๐›๐ข๐ญ๐จ๐ซ that targets the ๐จ๐ฏ๐ž๐ซ๐š๐œ๐ญ...
06/08/2026

Addressing ๐š๐œ๐ก๐จ๐ง๐๐ซ๐จ๐ฉ๐ฅ๐š๐ฌ๐ข๐š at its source ๐ˆ๐ง๐Ÿ๐ข๐ ๐ซ๐š๐ญ๐ข๐ง๐ข๐›, ๐š๐ง ๐จ๐ซ๐š๐ฅ ๐…๐†๐…๐‘๐Ÿโ€“๐Ÿ‘ ๐ญ๐ฒ๐ซ๐จ๐ฌ๐ข๐ง๐ž ๐ค๐ข๐ง๐š๐ฌ๐ž ๐ข๐ง๐ก๐ข๐›๐ข๐ญ๐จ๐ซ that targets the ๐จ๐ฏ๐ž๐ซ๐š๐œ๐ญ๐ข๐ฏ๐ž ๐…๐†๐…๐‘๐Ÿ‘ ๐ฌ๐ข๐ ๐ง๐š๐ฅ๐ข๐ง๐  underlying achondroplasia, significantly ๐ข๐ง๐œ๐ซ๐ž๐š๐ฌ๐ž๐ ๐š๐ง๐ง๐ฎ๐š๐ฅ๐ข๐ณ๐ž๐ ๐ก๐ž๐ข๐ ๐ก๐ญ ๐ฏ๐ž๐ฅ๐จ๐œ๐ข๐ญ๐ฒ ๐›๐ฒ ๐Ÿ.๐Ÿ•๐Ÿ’ ๐œ๐ฆ/๐ฒ๐ž๐š๐ซ versus placebo in the Phase 3 PROPEL 3 trial, while also ๐ข๐ฆ๐ฉ๐ซ๐จ๐ฏ๐ข๐ง๐  ๐ก๐ž๐ข๐ ๐ก๐ญ ๐ณ ๐ฌ๐œ๐จ๐ซ๐ž ๐จ๐ฏ๐ž๐ซ ๐Ÿ“๐Ÿ ๐ฐ๐ž๐ž๐ค๐ฌ (both P

05/08/2026

๐–๐จ๐ซ๐ฅ๐ ๐๐ซ๐ž๐š๐ฌ๐ญ๐Ÿ๐ž๐ž๐๐ข๐ง๐  ๐–๐ž๐ž๐คโฃ
โฃ
๐ƒ๐ซ. ๐€๐š๐ฒ๐ฎ๐ฌ๐ก๐ข ๐‰๐จ๐ฌ๐ก๐ข ๐๐š๐ฎ๐ญ๐ข๐ฒ๐š๐ฅ breaks down why breast milk isn't just nutrition โ€” it's a newborn's first vaccine, first immunity, and first medicine. All in one feed. ๐Ÿ’™โฃ
โฃ

04/08/2026

The first vaccine a newborn receives isn't an injection. ๐Ÿผ
โฃโฃ
This ๐–๐จ๐ซ๐ฅ๐ ๐๐ซ๐ž๐š๐ฌ๐ญ๐Ÿ๐ž๐ž๐๐ข๐ง๐  ๐–๐ž๐ž๐ค, we break down the science behind why breast milk is far more than nutrition โ€” it is immunisation, neurodevelopment, emotional security, and maternal health all in one.
โฃโฃ
๐Ÿ”— Watch. Share. Spread awareness.โฃโฃ

๐–๐จ๐ซ๐ฅ๐ ๐๐ซ๐ž๐š๐ฌ๐ญ๐Ÿ๐ž๐ž๐๐ข๐ง๐  ๐–๐ž๐ž๐ค ๐ข๐ฌ ๐ก๐ž๐ซ๐ž.โฃโฃโฃโฃLet's kick off with a simple question that sparks an important discussion. Follow a...
01/08/2026

๐–๐จ๐ซ๐ฅ๐ ๐๐ซ๐ž๐š๐ฌ๐ญ๐Ÿ๐ž๐ž๐๐ข๐ง๐  ๐–๐ž๐ž๐ค ๐ข๐ฌ ๐ก๐ž๐ซ๐ž.โฃโฃ
โฃโฃ
Let's kick off with a simple question that sparks an important discussion. Follow along all week for evidence-backed breastfeeding insights.โฃโฃ
โฃโฃ

๐‚๐€๐‘-๐“ ๐ญ๐ก๐ž๐ซ๐š๐ฉ๐ฒ is expanding beyond oncology into ๐š๐ฎ๐ญ๐จ๐ข๐ฆ๐ฆ๐ฎ๐ง๐ž ๐๐ข๐ฌ๐ž๐š๐ฌ๐ž. By targeting ๐š๐ฎ๐ญ๐จ๐ซ๐ž๐š๐œ๐ญ๐ข๐ฏ๐ž ๐ ๐œ๐ž๐ฅ๐ฅ๐ฌ, CAR-T ๐ซ๐ž๐๐ฎ๐œ๐ž๐ฌ ๐ฉ๐š๐ญ...
30/07/2026

๐‚๐€๐‘-๐“ ๐ญ๐ก๐ž๐ซ๐š๐ฉ๐ฒ is expanding beyond oncology into ๐š๐ฎ๐ญ๐จ๐ข๐ฆ๐ฆ๐ฎ๐ง๐ž ๐๐ข๐ฌ๐ž๐š๐ฌ๐ž.

By targeting ๐š๐ฎ๐ญ๐จ๐ซ๐ž๐š๐œ๐ญ๐ข๐ฏ๐ž ๐ ๐œ๐ž๐ฅ๐ฅ๐ฌ, CAR-T ๐ซ๐ž๐๐ฎ๐œ๐ž๐ฌ ๐ฉ๐š๐ญ๐ก๐จ๐ ๐ž๐ง๐ข๐œ ๐š๐ฎ๐ญ๐จ๐š๐ง๐ญ๐ข๐›๐จ๐๐ฒ ๐ฉ๐ซ๐จ๐๐ฎ๐œ๐ญ๐ข๐จ๐ง ๐š๐ง๐ ๐š๐ข๐ฆ๐ฌ ๐ญ๐จ ๐ซ๐ž๐ฌ๐ญ๐จ๐ซ๐ž ๐ข๐ฆ๐ฆ๐ฎ๐ง๐ž ๐ญ๐จ๐ฅ๐ž๐ซ๐š๐ง๐œ๐ž ๐ญ๐ก๐ซ๐จ๐ฎ๐ ๐ก ๐š๐ง ๐ข๐ฆ๐ฆ๐ฎ๐ง๐ž "๐ซ๐ž๐ฌ๐ž๐ญ."

Early clinical studies across diseases such as ๐ฌ๐ฒ๐ฌ๐ญ๐ž๐ฆ๐ข๐œ ๐ฅ๐ฎ๐ฉ๐ฎ๐ฌ ๐ž๐ซ๐ฒ๐ญ๐ก๐ž๐ฆ๐š๐ญ๐จ๐ฌ๐ฎ๐ฌ, ๐ฌ๐ฒ๐ฌ๐ญ๐ž๐ฆ๐ข๐œ ๐ฌ๐œ๐ฅ๐ž๐ซ๐จ๐ฌ๐ข๐ฌ, ๐š๐ง๐ ๐ฆ๐ฒ๐š๐ฌ๐ญ๐ก๐ž๐ง๐ข๐š ๐ ๐ซ๐š๐ฏ๐ข๐ฌ have reported sustained, drug-free remission in selected patients with refractory disease, supporting continued clinical investigation.

Expanding access to single-dose influenza treatment. The FDA has approved the ๐Ÿ๐ข๐ซ๐ฌ๐ญ ๐ ๐ž๐ง๐ž๐ซ๐ข๐œ ๐๐š๐ฅ๐จ๐ฑ๐š๐ฏ๐ข๐ซ ๐Œ๐š๐ซ๐›๐จ๐ฑ๐ข๐ฅ for the t...
27/07/2026

Expanding access to single-dose influenza treatment.

The FDA has approved the ๐Ÿ๐ข๐ซ๐ฌ๐ญ ๐ ๐ž๐ง๐ž๐ซ๐ข๐œ ๐๐š๐ฅ๐จ๐ฑ๐š๐ฏ๐ข๐ซ ๐Œ๐š๐ซ๐›๐จ๐ฑ๐ข๐ฅ for the treatment of ๐š๐œ๐ฎ๐ญ๐ž ๐ฎ๐ง๐œ๐จ๐ฆ๐ฉ๐ฅ๐ข๐œ๐š๐ญ๐ž๐ ๐ข๐ง๐Ÿ๐ฅ๐ฎ๐ž๐ง๐ณ๐š and ๐ฉ๐จ๐ฌ๐ญ-๐ž๐ฑ๐ฉ๐จ๐ฌ๐ฎ๐ซ๐ž ๐ฉ๐ซ๐จ๐ฉ๐ก๐ฒ๐ฅ๐š๐ฑ๐ข๐ฌ ๐ข๐ง ๐ฉ๐š๐ญ๐ข๐ž๐ง๐ญ๐ฌ ๐š๐ ๐ž๐ โ‰ฅ๐Ÿ“ ๐ฒ๐ž๐š๐ซ๐ฌ.

Indicated for use within ๐Ÿ’๐Ÿ– ๐ก๐จ๐ฎ๐ซ๐ฌ ๐จ๐Ÿ ๐ฌ๐ฒ๐ฆ๐ฉ๐ญ๐จ๐ฆ ๐จ๐ง๐ฌ๐ž๐ญ, the single-dose antiviral could improve timely access and affordability ahead of the 2026โ€“2027 influenza season.

New clinical evidence highlights the potential of a liquid ๐€๐ฒ๐ฎ๐ซ๐ฏ๐ž๐๐ข๐œ ๐ง๐ฎ๐ญ๐ซ๐š๐œ๐ž๐ฎ๐ญ๐ข๐œ๐š๐ฅ combining ๐ญ๐ฎ๐ซ๐ฆ๐ž๐ซ๐ข๐œ, ๐๐š๐ง๐๐ž๐ฅ๐ข๐จ๐ง, ๐ ๐ข๐ง๐ ๐ž๐ซ...
24/07/2026

New clinical evidence highlights the potential of a liquid ๐€๐ฒ๐ฎ๐ซ๐ฏ๐ž๐๐ข๐œ ๐ง๐ฎ๐ญ๐ซ๐š๐œ๐ž๐ฎ๐ญ๐ข๐œ๐š๐ฅ combining ๐ญ๐ฎ๐ซ๐ฆ๐ž๐ซ๐ข๐œ, ๐๐š๐ง๐๐ž๐ฅ๐ข๐จ๐ง, ๐ ๐ข๐ง๐ ๐ž๐ซ, ๐š๐ง๐ ๐ฆ๐ข๐ฅ๐ค ๐ญ๐ก๐ข๐ฌ๐ญ๐ฅ๐ž in ๐Œ๐€๐’๐‹๐ƒ. โฃ
โฃ
In a randomized, placebo-controlled trial, the formulation ๐ข๐ฆ๐ฉ๐ซ๐จ๐ฏ๐ž๐ ๐Ÿ๐š๐ญ๐ญ๐ฒ ๐ฅ๐ข๐ฏ๐ž๐ซ ๐ ๐ซ๐š๐๐ž ๐ข๐ง ๐Ÿ”๐ŸŽ% ๐จ๐Ÿ ๐ฉ๐š๐ซ๐ญ๐ข๐œ๐ข๐ฉ๐š๐ง๐ญ๐ฌ versus 13.3% with placebo and ๐ฌ๐ข๐ ๐ง๐ข๐Ÿ๐ข๐œ๐š๐ง๐ญ๐ฅ๐ฒ ๐ž๐ง๐ก๐š๐ง๐œ๐ž๐ ๐ฅ๐ข๐ฏ๐ž๐ซ ๐ก๐ž๐š๐ฅ๐ญ๐ก ๐ฆ๐š๐ซ๐ค๐ž๐ซ๐ฌ. โฃ
โฃ
With a favorable safety and tolerability profile, these findings offer promising early evidence for a multi-herbal approach to MASLD management.โฃ
โฃ
โฃ

Address

264-265, Drive Annie Besant Rd
Mumbai
400025

Opening Hours

Monday 10am - 6:30pm
Tuesday 10am - 6:30pm
Wednesday 10am - 6:30pm
Thursday 10am - 6:30pm
Friday 10am - 6:30pm
Saturday 10am - 6:30pm

Telephone

+918335822001

Website

Alerts

Be the first to know and let us send you an email when CLIRNET posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to CLIRNET:

Shortcuts

Share

Category